DM Clinical Trials

328 recruitingLast updated: June 18, 2026

There are 328 actively recruiting dm clinical trials across 59 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Houston, Texas, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


DM Trials at a Glance

328 actively recruiting trials for dm are listed on ClinicalTrialsFinder across 6 cities in 59 countries. The largest study group is Not Applicable with 106 trials, with the heaviest enrollment activity in Beijing, Houston, and Shanghai. Lead sponsors running dm studies include BrightGene Bio-Medical Technology Co., Ltd., Assistance Publique - Hôpitaux de Paris, and Dyne Therapeutics.

Treatments under study

About DM Clinical Trials

Looking for clinical trials for DM? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new DM trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about DM clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 328 trials

Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University420 enrolled7 locationsNCT06906640
Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University750 enrolled7 locationsNCT06906627
Recruiting
Early Phase 1

Simultaneous Measurement and Responsive Treatment - Part 2

Type 1 DiabetesType 1 Diabetes MellitusT1D+1 more
ClinSurge Research40 enrolled1 locationNCT07655076
Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting

Validity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)
Selcuk University75 enrolled1 locationNCT07649967
Recruiting
Phase 1

Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma (NDMM)Multiple Myloma
The First Affiliated Hospital of Soochow University18 enrolled1 locationNCT07652138
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled22 locationsNCT06845202
Recruiting
Phase 2

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals40 enrolled1 locationNCT07465224
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled16 locationsNCT07403721
Recruiting
Phase 2

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Colon CancerdMMR Colorectal Cancer
University of Iowa25 enrolled2 locationsNCT05239546
Recruiting
Not Applicable

The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment

Type 2 Diabetes Mellitus (T2DM)Mild Cognitive Impairment (MCI)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School40 enrolled1 locationNCT07650318
Recruiting

Longitudinal Studies of Patient With FPDMM

Rare DiseasesInherited Hematological DiseasesFPDMM
National Human Genome Research Institute (NHGRI)1,000 enrolled1 locationNCT03854318
Recruiting

A Remote Study Using Technology to Assess Outcomes in DMD

Duchenne Muscular Dystrophy (DMD)
University of Oxford60 enrolled1 locationNCT07423026
Recruiting

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Myotonic Dystrophy 1DM1
Virginia Commonwealth University700 enrolled17 locationsNCT03981575
Recruiting

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

Congenital Myotonic DystrophyCDM
Virginia Commonwealth University50 enrolled5 locationsNCT05224778
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled7 locationsNCT04732065
Recruiting
Not Applicable

Pediatric Insulin Plan Calculator for T1DM Management

Type 1 Diabetes Mellitus (T1DM)Type 1 Diabetes MellitusT1DM+1 more
Sultan Qaboos University440 enrolled2 locationsNCT07427134
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated52 enrolled26 locationsNCT06185764
Recruiting

Impact of Online Medical Misinformation

Medication AdherenceDiabetes (DM)Hypertension (HTN)+3 more
Alexandria University300 enrolled1 locationNCT07601308
Recruiting
Phase 2

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Duchenne Muscular DystrophyDMDNeuromuscular Diseases+2 more
Satellos Bioscience, Inc.51 enrolled21 locationsNCT07287189